UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

The New England journal of medicine, 2014-02, Vol.370 (8), p.709-722

2014

Volltextzugriff (PDF)

Tomotherapy for cranio-spinal irradiation

Clinical and translational radiation oncology, 2023-01, Vol.38, p.96-103

2023

Volltextzugriff (PDF)

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.521-528

2019

Volltextzugriff (PDF)

Deep-learning magnetic resonance imaging-based automatic segmentation for organs-at-risk in the brain: Accuracy and impact on dose distribution

Physics and imaging in radiation oncology, 2023-07, Vol.27, p.100454-100454, Article 100454

2023

Volltextzugriff (PDF)

Current provision and challenges for paediatric radiotherapy in Romania: A survey by the SIOP Europe QUARTET project

EJC paediatric oncology, 2023, Vol.1, p.100007, Article 100007

2023

Volltextzugriff (PDF)

695: Dose-Volume predictors of acute hematologic toxicity during pediatric cranio-spinal irradiation

Radiotherapy and oncology, 2024-05, Vol.194, p.S2024-S2026

2024

Volltextzugriff (PDF)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Frontiers in oncology, 2016-10, Vol.6, p.232-232

2016

Volltextzugriff (PDF)

Dynamics and predictors of hematologic toxicity during cranio-spinal irradiation

Reports of practical oncology and radiotherapy, 2024-07, Vol.29 (3), p.362-372

2024

Volltextzugriff (PDF)

ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi17-vi18

2017

Volltextzugriff (PDF)

Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2020-2020

2016

Volltextzugriff (PDF)

Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma

Journal of B.U. ON., 2016-01, Vol.21 (1), p.199-207

2016

Volltextzugriff (PDF)

ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi5-vi5

2016

Volltextzugriff (PDF)

AT-18 SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v12-v12

2014

Volltextzugriff (PDF)

BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio

Neuro-oncology (Charlottesville, Va.), 2016, Vol.18, p.5

2016

Volltextzugriff (PDF)

Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2005-2005

2013

Volltextzugriff (PDF)

AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v12-v12

2014

Volltextzugriff (PDF)

Survival analysis of patients with a PFS event who did not receive post-progression therapy in AVAglio (bevacizumab [BEV] plus radiotherapy [RT] and temozolomide [TMZ] for newly diagnosed glioblastoma [GBM])

Neuro-oncology (Charlottesville, Va.), 2014, Vol.16 (5)

2014

Volltextzugriff (PDF)

FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2013, Vol.15 (Supplement: 3), p.105

2013

Volltextzugriff (PDF)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Frontiers in oncology, 2016-10, Vol.6

2016

Volltextzugriff (PDF)

Surgery of high grade gliomas - pros in favor of maximal cytoreductive surgery

Romanian neurosurgery, 2011-03, Vol.18 (1)

2011

Volltextzugriff (PDF)

P2-205: Long term results of concurrent chemoradiotherapy with Vinorelbine and a Platinum compound followed by consolidation chemotherapy for advanced stage III Non-Small Lung cancer (NSCLC)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S652-S653

2007

Volltextzugriff (PDF)

P-593 Concurrent chemoradiotherapy with navelbine and cisplatin for unresectable stage III NSCLC: A phase II study

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S241-S241

2003

Volltextzugriff (PDF)

Other Radiotherapeutic Techniques

Pineal Region Lesions, p.127-130

Volltextzugriff (PDF)

External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement

The Laryngoscope, 2013-09, Vol.123 (S4), p.S1-S14

2013

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(30)
Buchkapitel
(1)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(10)
Oncology
(7)
Humans
(4)
Medicine, Research & Experimental
(3)
Otorhinolaryngology
(3)
Radiology, Nuclear Medicine & Medical Imaging
(3)
Research & Experimental Medicine
(3)
Abstracts
(2)
Adult
(2)
Aged
(2)
Brain Neoplasms - Drug Therapy
(2)
Brain Neoplasms - Pathology
(2)
Cetuximab
(2)
Dacarbazine - Analogs & Derivatives
(2)
Dacarbazine - Therapeutic Use
(2)
Double-Blind Method
(2)
Egfr
(2)
Female
(2)
Glioblastoma
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Tomotherapy for cranio-spinal irradiation

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Deep-learning magnetic resonance imaging-based automatic segmentation for organs-at-risk in the brain: Accuracy and impact on dose distribution

Current provision and challenges for paediatric radiotherapy in Romania: A survey by the SIOP Europe QUARTET project

695: Dose-Volume predictors of acute hematologic toxicity during pediatric cranio-spinal irradiation

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Dynamics and predictors of hematologic toxicity during cranio-spinal irradiation

ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA

Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio

Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma

ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio

AT-18 SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio

Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)

AT-18SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

Survival analysis of patients with a PFS event who did not receive post-progression therapy in AVAglio (bevacizumab [BEV] plus radiotherapy [RT] and temozolomide [TMZ] for newly diagnosed glioblastoma [GBM])

FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Surgery of high grade gliomas - pros in favor of maximal cytoreductive surgery

P2-205: Long term results of concurrent chemoradiotherapy with Vinorelbine and a Platinum compound followed by consolidation chemotherapy for advanced stage III Non-Small Lung cancer (NSCLC)

P-593 Concurrent chemoradiotherapy with navelbine and cisplatin for unresectable stage III NSCLC: A phase II study

Other Radiotherapeutic Techniques

External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement

International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal

Suchergebnisse filtern